The FDA has approved 40μg and 80μg strengths of Teva’s QVAR RediHaler beclomethasone dipropionate breath-actuated MDI for treatment of asthma in patients aged 4 and older, the company said. Teva said that it expects to launch the product in the US in the first quarter of 2018.
The current version of QVAR, which added a dose counter, was approved by the FDA in 2014. Teva plans to discontinue that product when it launches the RediHaler.
Teva Head of Late Stage Development Tushar Shah commented, “It’s important that we uncover new opportunities to take longstanding, clinically effective medications, such as QVAR, and incorporate them into device technologies that may help address key ongoing issues for patients, including inhaler technique. The FDA approval of QVAR RediHaler brings to market inhaler technology aimed at enabling patients to more accurately administer the medication and ensuring they are receiving a proper dose with each inhalation.”
Read the Teva press release.